Redox modifier genes and pathways in amyotrophic lateral sclerosis

Antioxidants and Redox Signaling

Volumn 11, Issue 7, 2009, Pages 1569-1586

  Carter, Barrie J ^a   Anklesaria, Pervin ^a   Choi, Stephanie ^b   Engelhardt, John F ^b  

^a Targeted Genetics Corporation   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEOL 10150; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; CARRIER PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CREATININE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 2; KNS 760704; MEMBRANE ASSOCIATED GUANYLATE KINASE INVERTED 2; MINOCYCLINE; NORPHENAZONE; PHOSPHOTRANSFERASE; PLACEBO; PROTEIN RAP1GAP; PROTEIN TIAM2; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE RECEPTOR TYPE T; PROTEINASE INHIBITOR; RAC PROTEIN; RAC1 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RILUZOLE; UBIDECARENONE; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DISEASE COURSE; DRUG MEGADOSE; ENZYME ACTIVITY; EXCITOTOXICITY; GENE EXPRESSION; GENE MUTATION; HUMAN; LOW DRUG DOSE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MICE, TRANSGENIC; NADPH OXIDASE; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE;

EID: 66749102059     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2008.2414     Document Type: Review

References (149)

1. Abe K, Pan LH, Watanabe M, Kato T, and Itoyama Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci Lett 199: 152-154, 1995.
2. Abe K, Pan LH, Watanabe M, Konno H, Kato T, and Itoyama Y. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol Res 19: 124-128, 1997.
3. Aricescu AR, Hon WC, Siebold C, Lu W, van der Merwe PA, and Jones EY. Molecular analysis of receptor protein tyrosine phosphatase mu-mediated cell adhesion. EMBO J 25: 701-712, 2006.
4. Aricescu AR, Siebold C, and Jones EY. Receptor protein tyrosine phosphatase micro: Measuring where to stick. Biochem Soc Trans 36: 167-172, 2008.
5. Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology 22: 217-228, 2003.
6. Arthur WT, Quilliam LA, and Cooper JA. Rap1 promotes cell spreading by localizing Rac guanine nucleotide exchange factors. J Cell Biol 167: 111-122, 2004.
7. Barber SC, Mead RJ, and Shaw PJ. Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762: 1051-1067, 2006.
8. Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, and Brown RH, Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644-654, 1997.
9. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidases: Physiology and patho-physiology. Physiol Rev 87: 245-313, 2007.
10. Beghi E, Logroscino G, Chio A, Hardiman O, Mitchell D, Swingler R, and Traynor BJ. The epidemiology of ALS and the role of population-based registries. Biochim Biophys Acta 1762: 1150-1157, 2006.
11. Bensimon G, Lacomblez L, and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. NEnglJMed 330: 585-591, 1994.
12. Besco J, Popesco MC, Davuluri RV, Frostholm A, and Rotter A. Genomic structure and alternative splicing of murine R2B receptor protein tyrosine phosphatases (PTPkappa, mu, rho and PCP-2). BMC Genomics 5: 14, 2004.
13. Boillee S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, and Cleveland DW. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312: 1389-1392, 2006.
14. Bonazzi M, Spano S, Turacchio G, Cericola C, Valente C, Colanzi A, Kweon HS, Hsu VW, Polishchuck EV, Polishchuck RS, Sallese M, Pulvirenti T, Corda D, and Luini A. CtBP3/BARS drives membrane fission in dynamin-independent transport pathways. Nat Cell Biol 7: 570-580, 2005.
15. Bos JL, Rehmann H, and Wittinghofer A. GEFs and GAPs: Critical elements in the control of small G proteins. Cell 129: 865-877, 2007.
16. Bowler RP, Sheng H, Enghild JJ, Pearlstein RD, Warner DS, and Crapo JD. A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. Free Radic Biol Med 33: 1141-1152, 2002.
17. Brandt DT and Grosse R. Get to grips: Steering local actin dynamics with IQGAPs. EMBO Rep 8: 1019-1023, 2007.
18. Briggs MW and Sacks DB. IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep 4: 571-574, 2003.
19. Brill S, Li S, Lyman CW, Church DM, Wasmuth JJ, Weissbach L, Bernards A, and Snijders AJ. The Ras GTPase-activating-protein-related human protein IQGAP2 harbors a potential actin binding domain and interacts with calmodulin and Rho family GTPases. Mol Cell Biol 16: 4869-4878, 1996.
20. Brown RH, Jr. and Robberecht W. Amyotrophic lateral sclerosis: Pathogenesis. Semin Neurol 21: 131-139, 2001.
21. Bruijn LI, Miller TM, and Cleveland DW. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27: 723-749, 2004.
22. Bustelo XR. Vav proteins, adaptors and cell signaling. Oncogene 20: 6372-6381, 2001.
23. Cai H, Lin X, Xie C, Laird FM, Lai C, Wen H, Chiang HC, Shim H, Farah MH, Hoke A, Price DL, and Wong PC. Loss of ALS2 function is insufficient to trigger motor neuron degeneration in knock-out mice but predisposes neurons to oxidative stress. J Neurosci 25: 7567-7574, 2005.
24. Carri MT, Grignaschi G, and Bendotti C. Targets in ALS: Designing multidrug therapies. Trends Pharmacol Sci 27: 267-273, 2006.
25. Chance B, Sies H, and Boveris A. Hydroperoxide metabolism in mammalian organs. Physiol Rev 59: 527-605, 1979.
26. Chandran J, Ding J, and Cai H. Alsin and the molecular pathways of amyotrophic lateral sclerosis. Mol Neurobiol 36: 224-231, 2007.
27. Chiu CY, Leng S, Martin KA, Kim E, Gorman S, and Duhl DM. Cloning and characterization of T-cell lymphoma invasion and metastasis 2 (TIAM2), a novel guanine nucleotide exchange factor related to TIAM1. Genomics 61: 66-73, 1999.
28. Choudry RB and Cudkowicz ME. Clinical trials in amyotrophic lateral sclerosis: The tenuous past and the promising future. J Clin Pharmacol 45: 1334-1344, 2005.
29. Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, Brown RH, Jr., Julien JP, Goldstein LS, and Cleveland DW. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302: 113-117, 2003.
30. Crow JP, Calingasan NY, Chen J, Hill JL, and Beal MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258-265, 2005.
31. Damke H, Baba T, van der Bliek AM, and Schmid SL. Clathrin-independent pinocytosis is induced in cells over-expressing a temperature-sensitive mutant of dynamin. J Cell Biol 131: 69-80, 1995.
32. Delanty N and Dichter MA. Antioxidant therapy in neurologic disease. Arch Neurol 57: 1265-1270, 2000.
33. Dengler R, von Neuhoff N, Bufler J, Krampfl K, Peschel T, and Grosskreutz J. Amyotrophic lateral sclerosis: New developments in diagnostic markers. Neurodegener Dis 2: 177-184, 2005.
34. Devon RS, Orban PC, Gerrow K, Barbieri MA, Schwab C, Cao LP, Helm JR, Bissada N, Cruz-Aguado R, Davidson TL, Witmer J, Metzler M, Lam CK, Tetzlaff W, Simpson EM, McCaffery JM, El-Husseini AE, Leavitt BR, and Hayden MR. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc Natl Acad Sci USA 103: 9595-9600, 2006.
35. Dib M. Amyotrophic lateral sclerosis: progress and prospects for treatment. Drugs 63: 289-310, 2003.
36. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 47: S233-241, 1996.
37. Dunckley T, Huentelman MJ, Craig DW, Pearson JV, Szelinger S, Joshipura K, Halperin RF, Stamper C, Jensen KR, Letizia D, Hesterlee SE, Pestronk A, Levine T, Bertorini T, Graves MC, Mozaffar T, Jackson CE, Bosch P, McVey A, Dick A, Barohn R, Lomen-Hoerth C, Rosenfeld J, O'Connor D T, Zhang K, Crook R, Ryberg H, Hutton M, Katz J, Simpson EP, Mitsumoto H, Bowser R, Miller RG, Appel SH, and Stephan DA. Whole-genome analysis of sporadic amyotrophic lateral sclerosis. N Engl J Med 357: 775-788, 2007.
38. Eisen A and Krieger C. Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice. New York, NY: Cambridge University Press, 1998.
39. el Benna J, Ruedi JM, and Babior BM. Cytosolic guanine nucleotide-binding protein Rac2 operates in vivo as a component of the neutrophil respiratory burst oxidase. Transfer of Rac2 and the cytosolic oxidase components p47phox and p67phox to the submembranous actin cyto-skeleton during oxidase activation. J Biol Chem 269: 6729-6734, 1994.
40. Erie EA, Shim H, Smith AL, Lin X, Keyvanfar K, Xie C, Chen J, and Cai H. Mice deficient in the ALS2 gene exhibit lymphopenia and abnormal hematopietic function. J Neuroimmunol 182: 226-231, 2007.
41. Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, and Cudkowicz M. Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS. Neurology 65: 1834-1836, 2005.
42. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH, Jr., and Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064-2074, 1997.
43. Fukuyama T, Ogita H, Kawakatsu T, Inagaki M, and Takai Y. Activation of Rac by cadherin through the c-Src-Rap1-phosphatidylinositol 3-kinase-Vav2 pathway. Oncogene 25: 8-19, 2006.
44. Galbussera A, Tremolizzo L, Brighina L, Testa D, Lovati R, Ferrarese C, Cavaletti G, and Filippini G. Vitamin E intake and quality of life in amyotrophic lateral sclerosis patients: A follow-up case series study. Neurol Sci 27: 190-193, 2006.
45. Gianni D, Bohl B, Courtneidge SA, and Bokoch GM. The involvement of the tyrosine kinase c-src in the regulation of reactive oxygen species generation mediated by NADPH oxidase-1. Mol Biol Cell 19: 2984-2994, 2008.
46. Goodall EF and Morrison KE. Amyotrophic lateral sclerosis (motor neuron disease): Proposed mechanisms and pathways to treatment. Expert Rev Mol Med 8: 1-22, 2006.
47. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, and Tandan R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurol 6: 1045-1053, 2007.
48. Gorin Y, Ricono JM, Kim NH, Bhandari B, Choudhury GG, and Abboud HE. Nox4 mediates angiotensin II-induced activation of Akt/protein kinase B in mesangial cells. Am J Physiol Renal Physiol 285: F219-229, 2003.
49. Gowing G, Dequen F, Soucy G, and Julien JP. Absence of tumor necrosis factor-alpha does not affect motor neuron disease caused by superoxide dismutase 1 mutations. J Neurosci 26: 11397-11402, 2006.
50. Gribkoff VK and Bozik ME. KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl- 2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis. CNS Neurosci Ther 14: 215-226, 2008.
51. Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, Wokke JH, Franssen H, and van den Berg LH. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53: 437-445, 2003.
52. Gros-Louis F, Gaspar C, and Rouleau GA. Genetics of familial and sporadic amyotrophic lateral sclerosis. Biochim Biophys Acta 1762: 956-972, 2006.
53. Habets GG, van der Kammen RA, Stam JC, Michiels F, and Collard JG. Sequence of the human invasion-inducing TIAM1 gene, its conservation in evolution and its expression in tumor cell lines of different tissue origin. Oncogene 10: 1371-1376, 1995.
54. Hadano S, Kunita R, Otomo A, Suzuki-Utsunomiya K, and Ikeda JE. Molecular and cellular function of ALS2/alsin: Implication of membrane dynamics in neuronal development and degeneration. Neurochem Int 51: 74-84, 2007.
55. Harraz MM, Marden JJ, Zhou W, Zhang Y, Williams A, Sharov VS, Nelson K, Luo M, Paulson H, Schoneich C, and Engelhardt JF. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest 118: 659-670, 2008.
56. Hart MJ, Callow MG, Souza B, and Polakis P. IQGAP1, a calmodulin-binding protein with a rasGAP-related domain, is a potential effector for cdc42Hs. EMBO J 15: 2997-3005, 1996.
57. Heath PR and Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve 26: 438-458, 2002.
58. Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, Alexander BK, Byers N, Toman I, and Alexander GM. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J Neurol Sci 236: 1-7, 2005.
59. Hensley K, Fedynyshyn J, Ferrell S, Floyd RA, Gordon B, Grammas P, Hamdheydari L, Mhatre M, Mou S, Pye QN, Stewart C, West M, West S, and Williamson KS. Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis 14: 74-80, 2003.
60. Hordijk PL. Regulation of NADPH oxidases: The role of Rac proteins. Circ Res 98: 453-462, 2006.
61. Hoshino M, Sone M, Fukata M, Kuroda S, Kaibuchi K, Nabeshima Y, and Hama C. Identification of the stef gene that encodes a novel guanine nucleotide exchange factor specific for Rac1. J Biol Chem 274: 17837-17844, 1999.
62. ALS Association website: http://www.alsa.org. Calabasas Hills, CA.
63. Knopp Neuroscience Inc website: http://www.knoppneurosciences.com. Pittsburgh, PA.
64. Hu Y, Li Z, Guo L, Wang L, Zhang L, Cai X, Zhao H, and Zha X. MAGI-2 inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells. Arch Biochem Biophys 467: 1-9, 2007.
65. Ikeda S, Yamaoka-Tojo M, Hilenski L, Patrushev NA, Anwar GM, Quinn MT, and Ushio-Fukai M. IQGAP1 regulates reactive oxygen species-dependent endothelial cell migration through interacting with Nox2. Arterioscler Thromb Vasc Biol 25: 2295-2300, 2005.
66. Irani K, Xia Y, Zweier JL, Sollott SJ, Der CJ, Fearon ER, Sundaresan M, Finkel T, and Goldschmidt-Clermont PJ. Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 275: 1649-1652, 1997.
67. Jeong HW, Li Z, Brown MD, and Sacks DB. IQGAP1 binds Rap1 and modulates its activity. J Biol Chem 282: 20752-20762, 2007.
68. Kabe Y, Ando K, Hirao S, Yoshida M, and Handa H. Redox regulation of NF-kappaB activation: Distinct redox regulation between the cytoplasm and the nucleus. Antioxid Redox Signal 7: 395-403, 2005.
69. Kanekura K, Hashimoto Y, Niikura T, Aiso S, Matsuoka M, and Nishimoto I. Alsin, the product of ALS2 gene, suppresses SOD1 mutant neurotoxicity through RhoGEF domain by interacting with SOD1 mutants. J Biol Chem 279: 19247-19256, 2004.
70. Kawauchi T, Chihama K, Nabeshima Y, and Hoshino M. The in vivo roles of STEF/Tiam1, Rac1 and JNK in cortical neuronal migration. EMBO J 22: 4190-4201, 2003.
71. Kheradmand F, Werner E, Tremble P, Symons M, and Werb Z. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 280: 898-902, 1998.
72. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, and Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5: 347-350, 1999.
73. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, and Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. JNeurochem 88: 576-582, 2004.
74. Kooistra MR, Dube N, and Bos JL. Rap1: A key regulator in cell-cell junction formation. J Cell Sci 120: 17-22, 2007.
75. Kriz J, Nguyen MD, and Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268-278, 2002.
76. Kunita R, Otomo A, Mizumura H, Suzuki-Utsunomiya K, Hadano S, and Ikeda JE. The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-activated endocytosis. J Biol Chem 282: 16599-16611, 2007.
77. Kuroda S, Fukata M, Kobayashi K, Nakafuku M, Nomura N, Iwamatsu A, and Kaibuchi K. Identification of IQGAP as a putative target for the small GTPases, Cdc42 and Rac1. J Biol Chem 271: 23363-23367, 1996.
78. Kuroda S, Fukata M, Nakagawa M, Fujii K, Nakamura T, Ookubo T, Izawa I, Nagase T, Nomura N, Tani H, Shoji I, Matsuura Y, Yonehara S, and Kaibuchi K. Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin-mediated cell-cell adhesion. Science 281: 832-835, 1998.
79. Lacomblez L, Bensimon G, Leigh PN, Guillet P, and Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347: 1425-1431, 1996.
80. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4: 181-189, 2004.
81. Lanka V and Cudkowicz M. Therapy development for ALS: Lessons learned and path forward. Amyotroph Lateral Scler 9: 131-140, 2008.
82. Li Q, Harraz MM, Zhou W, Zhang LN, Ding W, Zhang Y, Eggleston T, Yeaman C, Banfi B, and Engelhardt JF. Nox2 and Rac1 regulate H2O2-dependent recruitment of TRAF6 to endosomal interleukin-1 receptor complexes. Mol Cell Biol 26: 140-154, 2006.
83. Li Q, Spencer NY, Oakley FD, Buettner GR, and Engelhardt JF. Endosomal Nox2 facilitates redox-dependent induction of NF-kB by TNF-a. Antioxid Redox Signal 11: 1249-1263, 2009.
84. nd, Paranavitana NC, Peng X, Kim C, Munugalavadla V, Kapur R, Chen H, Shou W, Stone JC, Kaplan MH, Dinauer MC, Durden DL, and Quilliam LA. Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol 179: 8322-8331, 2007.
85. Liliental J, Moon SY, Lesche R, Mamillapalli R, Li D, Zheng Y, Sun H, and Wu H. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol 10: 401-404, 2000.
86. Lobsiger CS and Cleveland DW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 10: 1355-1360, 2007.
87. Lopes N, Gregg D, Vasudevan S, Hassanain H, Goldschmidt-Clermont P, and Kovacic H. Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling. Mol Cell Biol 23: 5401-5408, 2003.
88. Lynch RE and Fridovich I. Permeation of the erythrocyte stroma by superoxide radical. J Biol Chem 253: 4697-4699, 1978.
89. Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, and Gage FH. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell 3: 649-657, 2008.
90. Marden JJ, Harraz MM, Williams AJ, Nelson K, Luo M, Paulson H, and Engelhardt JF. Redox modifier genes in amyotrophic lateral sclerosis in mice. J Clin Invest 117: 2913-2919, 2007.
91. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, and Knaus UG. Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18: 69-82, 2006.
92. Mataraza JM, Briggs MW, Li Z, Entwistle A, Ridley AJ, and Sacks DB. IQGAP1 promotes cell motility and invasion. J Biol Chem 278: 41237-41245, 2003.
93. Matsuo N, Hoshino M, Yoshizawa M, and Nabeshima Y. Characterization of STEF, a guanine nucleotide exchange factor for Rac1, required for neurite growth. J Biol Chem 277: 2860-2868, 2002.
94. McCord JM and Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244: 6049-6055, 1969.
95. Mertens AE, Roovers RC, and Collard JG. Regulation of Tiam1-Rac signalling. FEBS Lett 546: 11-16, 2003.
96. Michiels F, Habets GG, Stam JC, van der Kammen RA, and Collard JG. A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature 375: 338-340, 1995.
97. Miller FJ, Jr., Filali M, Huss GJ, Stanic B, Chamseddine A, Barna TJ, and Lamb FS. Cytokine activation of nuclear factor kappa B in vascular smooth muscle cells requires signaling endosomes containing Nox1 and ClC-3. Circ Res 101: 663-671, 2007.
98. Ming W, Li S, Billadeau DD, Quilliam LA, and Dinauer MC. The Rac effector p67phox regulates phagocyte NADPH oxidase by stimulating Vav1 guanine nucleotide exchange activity. Mol Cell Biol 27: 312-323, 2007.
99. Moore KA, Sethi R, Doanes AM, Johnson TM, Pracyk JB, Kirby M, Irani K, Goldschmidt-Clermont PJ, and Finkel T. Rac1 is required for cell proliferation and G2/M progression. Biochem J 326: 17-20, 1997.
100. Mumbengegwi DR, Li Q, Li C, Bear CE, and Engelhardt JF. Evidence for a superoxide permeability pathway in endosomal membranes. Mol Cell Biol 28: 3700-3712, 2008.
101. Nguyen MD, Julien JP, and Rivest S. Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: No requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann Neurol 50: 630-639, 2001.
102. Nimnual AS, Taylor LJ, and Bar-Sagi D. Redox-dependent downregulation of Rho by Rac. Nat Cell Biol 5: 236-241, 2003.
103. Oakley FD, Abbott D, Li Q, and Engelhardt JF. Signaling components of redox active endosomes: The redoxosomes. Antioxid Redox Signal 11: 1313-1333, 2009.
104. Orrell RW. AEOL-10150 (Aeolus). Curr Opin Investig Drugs 7: 70-80, 2006.
105. Orrell RW, Lane RJ, and Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Amyotroph Lat Scler 9: 195-211, 2008.
106. Otomo A, Hadano S, Okada T, Mizumura H, Kunita R, Nishijima H, Showguchi-Miyata J, Yanagisawa Y, Kohiki E, Suga E, Yasuda M, Osuga H, Nishimoto T, Narumiya S, and Ikeda JE. ALS2, a novel guanine nucleotide exchange factor for the small GTPase Rab5, is implicated in endosomal dynamics. Hum Mol Genet 12: 1671-1687, 2003.
107. Palamidessi A, Frittoli E, Garre M, Faretta M, Mione M, Testa I, Diaspro A, Lanzetti L, Scita G, and Di Fiore PP. Endocytic trafficking of Rac is required for the spatial restriction of signaling in cell migration. Cell 134: 135-147, 2008.
108. Pani G, Colavitti R, Bedogni B, Anzevino R, Borrello S, and Galeotti T. A redox signaling mechanism for density-dependent inhibition of cell growth. J Biol Chem 275: 38891-38899, 2000.
109. Pasinelli P and Brown RH. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat Rev Neurosci 7: 710-723, 2006.
110. Phillips-Mason PJ, Gates TJ, Major DL, Sacks DB, and Brady-Kalnay SM. The receptor protein-tyrosine phosphatase PTPmu interacts with IQGAP1. J Biol Chem 281: 4903-4910, 2006.
111. Poloni M, Facchetti D, Mai R, Micheli A, Agnoletti L, Francolini G, Mora G, Camana C, Mazzini L, and Bachetti T. Circulating levels of tumour necrosis factor-alpha and its soluble receptors are increased in the blood of patients with amyotrophic lateral sclerosis. Neurosci Lett 287: 211-214, 2000.
112. Polymenidou M and Cleveland DW. Motor neuron disease: The curious ways of ALS. Nature 454: 284-285, 2008.
113. Puceat M, Travo P, Quinn MT, and Fort P. A dual role of the GTPase Rac in cardiac differentiation of stem cells. Mol Biol Cell 14: 2781-2792, 2003.
114. Quinn MT, Parkos CA, Walker L, Orkin SH, Dinauer MC, and Jesaitis AJ. Association of a Ras-related protein with cytochrome b of human neutrophils. Nature 342: 198-200, 1989.
115. Remans PH, Gringhuis SI, van Laar JM, Sanders ME, Papendrecht-van der Voort EA, Zwartkruis FJ, Levarht EW, Rosas M, Coffer PJ, Breedveld FC, Bos JL, Tak PP, Verweij CL, and Reedquist KA. Rap1 signaling is required for suppression of Ras-generated reactive oxygen species and protection against oxidative stress in T lymphocytes. J Immunol 173: 920-931, 2004.
116. Roepstorff K, Rasmussen I, Sawada M, Cudre-Maroux C, Salmon P, Bokoch G, van Deurs B, and Vilhardt F. Stimulus-dependent regulation of the phagocyte NADPH oxidase by a VAV1, Rac1, and PAK1 signaling axis. J Biol Chem 283: 7983-7993, 2008.
117. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX, and et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62, 1993.
118. Sakurai A, Fukuhara S, Yamagishi A, Sako K, Kamioka Y, Masuda M, Nakaoka Y, and Mochizuki N. MAGI-1 is required for Rap1 activation upon cell-cell contact and for enhancement of vascular endothelial cadherin-mediated cell adhesion. Mol Biol Cell 17: 966-976, 2006.
119. Salvador A, Sousa J, and Pinto RE. Hydroperoxyl, superoxide and pH gradients in the mitochondrial matrix: a theoretical assessment. Free Radic Biol Med 31: 1208-1215, 2001.
120. Schmidt VA, Scudder L, Devoe CE, Bernards A, Cupit LD, and Bahou WF. IQGAP2 functions as a GTP-dependent effector protein in thrombin-induced platelet cytoskeletal reorganization. Blood 101: 3021-3028, 2003.
121. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N, Bostrom A, Theodoss J, Al-Nakhala BM, Vieira FG, Ramasubbu J, and Heywood JA. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9: 4-15, 2008.
122. Shaw PJ, Ince PG, Falkous G, and Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol 38: 691-695, 1995.
123. Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli L, Qureshi M, Zhang H, Pestronk A, Caress J, Donofrio P, Sorenson E, Bradley W, Lomen-Hoerth C, Pioro E, Rezania K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitsumoto H, Rothstein J, Smith-Palmer T, MacDonald D, and Burke D. A clinical trial of creatine in ALS. Neurology 63: 1656-1661, 2004.
124. Shefner JM, Cudkowicz ME, Zhang H, Schoenfeld D, and Jillapalli D. The use of statistical MUNE in a multicenter clinical trial. Muscle Nerve 30: 463-469, 2004.
125. Shoulson I. Experimental therapeutics of neurodegenerative disorders: Unmet needs. Science 282: 1072-1074, 1998.
126. Simpson EP, Yen AA, and Appel SH. Oxidative stress: A common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr Opin Rheumatol 15: 730-736, 2003.
127. Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, Lobsiger CS, Ward CM, McAlonis-Downes M, Wei H, Wancewicz EV, Bennett CF, and Cleveland DW. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116: 2290-2296, 2006.
128. Subauste MC, Nalbant P, Adamson ED, and Hahn KM. Vinculin controls PTEN protein level by maintaining the interaction of the adherens junction protein beta-catenin with the scaffolding protein MAGI-2. J Biol Chem 280: 5676-5681, 2005.
129. Sulciner DJ, Irani K, Yu ZX, Ferrans VJ, Goldschmidt-Clermont P, and Finkel T. rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kappaB activation. Mol Cell Biol 16: 7115-7121, 1996.
130. Topp JD, Carney DS, and Horazdovsky BF. Biochemical characterization of Alsin, a Rab5 and Rac1 guanine nucleotide exchange factor. Methods Enzymol 403: 261-276, 2005.
131. Topp JD, Gray NW, Gerard RD, and Horazdovsky BF. Alsin is a Rab5 and Rac1 guanine nucleotide exchange factor. J Biol Chem 279: 24612-24623, 2004.
132. Traynor BJ, Bruijn L, Conwit R, Beal F, O'Neill G, Fagan SC, and Cudkowicz ME. Neuroprotective agents for clinical trials in ALS: A systematic assessment. Neurology 67: 20-27, 2006.
133. Vallet P, Charnay Y, Steger K, Ogier-Denis E, Kovari E, Herrmann F, Michel JP, and Szanto I. Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia. Neuroscience 132: 233-238, 2005.
134. Van Den Bosch L, Tilkin P, Lemmens G, and Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 13: 1067-1070, 2002.
135. Vazquez F, Grossman SR, Takahashi Y, Rokas MV, Nakamura N, and Sellers WR. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem 276: 48627-48630, 2001.
136. Wang S, Watanabe T, Noritake J, Fukata M, Yoshimura T, Itoh N, Harada T, Nakagawa M, Matsuura Y, Arimura N, and Kaibuchi K. IQGAP3, a novel effector of Rac1 and Cdc42, regulates neurite outgrowth. J Cell Sci 120: 567-577, 2007.
137. Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CY, and Landreth G. Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem 281: 20842-20850, 2006.
138. Woo CH, Kim TH, Choi JA, Ryu HC, Lee JE, You HJ, Bae YS, and Kim JH. Inhibition of receptor internalization attenuates the TNFalpha-induced ROS generation in nonphagocytic cells. Biochem Biophys Res Commun 351: 972-978, 2006.
139. Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA, and Seburn KL. Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 32: 43-50, 2005.
140. Worthylake DK, Rossman KL, and Sondek J. Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1. Nature 408: 682-688, 2000.
141. Wu DC, Re DB, Nagai M, Ischiropoulos H, and Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci USA 103: 12132-12137, 2006.
142. Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ, Wood J, Ross C, Sawyers CL, and Whang YE. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci USA 97: 4233-4238, 2000.
143. Yamaoka-Tojo M, Ushio-Fukai M, Hilenski L, Dikalov SI, Chen YE, Tojo T, Fukai T, Fujimoto M, Patrushev NA, Wang N, Kontos CD, Bloom GS, and Alexander RW. IQGAP1, a novel vascular endothelial growth factor receptor binding protein, is involved in reactive oxygen species-dependent endothelial migration and proliferation. Circ Res 95: 276-283, 2004.
144. Yang Y, Hentati A, Deng HX, Dabbagh O, Sasaki T, Hirano M, Hung WY, Ouahchi K, Yan J, Azim AC, Cole N, Gascon G, Yagmour A, Ben-Hamida M, Pericak-Vance M, Hentati F, and Siddique T. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29: 160-165, 2001.
145. Yoshino H and Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler 7: 241-245, 2006.
146. Yoshizawa M, Hoshino M, Sone M, and Nabeshima Y. Expression of stef, an activator of Rac1, correlates with the stages of neuronal morphological development in the mouse brain. Mech Dev 113: 65-68, 2002.
147. Zaldua N, Gastineau M, Hoshino M, Lezoualc'h F, and Zugaza JL. Epac signaling pathway involves STEF, a guanine nucleotide exchange factor for Rac, to regulate APP processing. FEBS Lett 581: 5814-5818, 2007.
148. Zhang W, Narayanan M, and Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53: 267-270, 2003.
149. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, and Friedlander RM. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature 417: 74-78, 2002.